FRANCESCO IACOBELLI: Open Payments
NPI 1750737706 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$893 in 42 payments from 16 companies in 2025. Trend: 2023 $805 · 2024 $1,007 · 2025 $893
Food & beverage: $893
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $112 |
| Corium, LLC | 5 | $107 |
| E.R. Squibb & Sons, L.L.C. | 4 | $93 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $88 |
| Axsome Therapeutics, Inc. | 3 | $77 |
| ABBVIE INC. | 3 | $72 |
| Collegium Pharmaceutical, Inc. | 3 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Janssen Pharmaceuticals, Inc | 1 | $34 |
Products named: INGREZZA, Azstarys, COBENFY, CAPLYTA, Auvelity, VRAYLAR, REXULTI, Jornay PM.
Industry payments across MI — which companies pay providers there.
